ArticleBMC global and public health2026
The epidemiological impact, costs, and cost-effectiveness of implementing household contact investigation with tuberculosis preventive treatment in Nepal: a model-based analysis.
Article in BMC global and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe burden of tuberculosis (TB) remains extremely high globally. It is increasingly recognized that contact investigation and preventive treatment are essential components of effective action to reduce TB. High-quality, local evidence of feasibility and impact is urgently needed to catalyse scale-up of preventive treatment in high-burden, resource-constrained settings.
methodsWe collected data on the costs and yields of contact investigation and implementation of three months of isoniazid and rifapentine (3HP) to treat latent TB infection (LTBI), among adult household members of people diagnosed with TB, from a pilot conducted in two districts of Nepal (Chitwan and Pyuthan) from August 2022 to March 2023. We developed and calibrated mathematical models representing each district and estimated the number of TB episodes and deaths averted by the intervention during 2023-2042. By combining net discounted costs and discounted impact, we estimated the incremental cost-effectiveness of the intervention (compared to no intervention) from a health system perspective as costs (United States Dollars (USD) in 2022) per disability-adjusted life-year (DALY) averted.
resultsThe intervention screened 1,711 adult household contact persons for TB and LTBI, and treated 500 individuals for LTBI, achieving 98% 3HP acceptance and 95% completion at 150 USD per contact person treated (including drug and test procurement and implementation costs). Including the impact of treating TB disease, the intervention was projected to avert 141 (95% Uncertainty Interval (UI): 86-224) disease episodes and 24 (95% UI: 13-39) deaths during 2023-2042, or 8.2 episodes and 1.4 deaths averted per 100 contact persons screened. The incremental cost-effectiveness of the intervention was 119 USD (95% UI: 51-255) and 163 USD (95% UI: 76-328) per DALY averted in Chitwan and Pyuthan, respectively.
conclusionsScreening and treating household members of people with TB for both TB and LTBI can be successfully implemented in both rural and urban settings, is highly cost-effective and should be prioritized to reduce the TB burden in Nepal and similar high-burden countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.